Vantage Consulting Group’s CONMED CNMD Stock Holding History

Vantage Consulting Group’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-476	Closed	-$53K	–	402
2020 Q4	$53K	Buy	+476	New	+$45.1K	﹤0.01%	412

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vantage Consulting Group's CNMD Position: Q1 2021 in Review

Vantage Consulting Group sold out of CONMED (CNMD) in Q1 2021, closing a stake of 476 shares — an estimated $53K sold.

Vantage Consulting Group first reported a position in CNMD in Q4 2020 and held it in 1 quarter. The position peaked at $53K in Q4 2020. 239 funds tracked by Wall St. Rank hold CNMD as of Q1 2021.

Vantage Consulting Group reported no remaining CONMED position as of Q1 2021 after selling out during the quarter.
Vantage Consulting Group sold 476 CONMED shares in Q1 2021, an estimated $53K.
Vantage Consulting Group first reported a position in CONMED in Q4 2020 and held it in 1 quarter.
Vantage Consulting Group's CONMED position peaked at $53K in Q4 2020.
239 funds tracked by Wall St. Rank held CONMED as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.